Phase 3 N=213 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis · Hyperphosphatemia
Primary: Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment — 5.00; 5.34 mg/dL — p=0.020
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=183 PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Chronic Kidney Disease Requiring Hemodialysis
Primary: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment. — -1.84; -2.59; -3.17; -3.78 mg/dL
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
N/A N=16 Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Phase 2 N=154 Study of Phosphate Levels in Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline in Serum-phosphate Levels at the End of Treatment. — -0.042; -0.348; -0.404; -0.644 mmol/L
Phase 3 N=30 Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
N/A N=31 Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Albuminuria
Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05
Phase 3 N=35 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis · Hyperphosphatemia
Primary: Incidence of Adverse Events — 28 Participants
N/A N=53 Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?
Chronic Renal Failure
Primary: Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron. — 3.47 mg/dL
Phase 2 N=153 Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
Hyperphosphataemia
Primary: Change in Serum Phosphate Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) — -0.4; -0.59; -1.29; -1.363 mg/dL — p=0.784
Phase 3 N=123 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 45 Participants — p=<0.0001
Phase 3 N=122 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 42 Participants — p=<0.0001
Phase 3 N=151 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Hyperphosphatemia · End-Stage Renal Disease
Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001
N/A N=43 Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Phase 4 N=17 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Peritoneal Dialysis Complication · Hyperphosphatemia · Hypoalbuminemia
Primary: Serum Phosphate at Baseline — 7.47 mg/dL
N/A N=18 FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
Phase 3 N=161 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis Patients With Hyperphosphatemia
Primary: Incidence of Adverse Events — 152 Participants
Phase 2 N=162 Dose Finding Study to Treat High Phosphate Levels in the Blood.
Hyperphosphatemia
Primary: Change in Serum Phosphate Levels — -.47; -1.18; -1.7; -1.98 mg/dL — p=0.012
Phase 3 N=202 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Hyperphosphatemia
Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001
N/A N=26 Racial Differences in Phosphorus Metabolism
Control
Primary: Urinary Phosphorus Excretion — 11 percentage of fractional excretion
Phase 2 N=55 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Phase 4 N=172 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Hyperphosphatemia · End Stage Renal Disease
Primary: Achieving Normal Serum Phosphorus Level — 36; 21 Participants — p=0.7439
Phase 2 N=101 An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
Hyperphosphatemia · Chronic Kidney Disease
Primary: Change From Baseline (Week 0) to Week 2 in Serum Phosphorus — 7.2; 7.2; 7.24; 6.34 mg/dL — p=0.001
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
N/A N=145 A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
Chronic Kidney Disease
Primary: Serum Phosphorus — 3.9; 4.2 mg/dL
Phase 3 N=1,059 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Change in Serum Phosphorus Levels From Week 24 to Week 27 — 0.25; 1.92 mg/dL
Phase 4 N=333 Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Chronic Kidney Disease Requiring Chronic Dialysis · Hyperphosphatemia
Primary: Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dL — 52; 58; 19 Participants
Phase 4 N=61 Phosphate Lowering in CKD Trial
Chronic Kidney Disease · Cardiovascular Disease
Primary: Brachial Artery Flow-mediated Dilation — 3.13; 3.74; 2.73; 3.09 percent change FMD
Phase 3 N=182 Head to Head Study Against Sevelamer Hydrochloride
Chronic Kidney Disease, Stage 5
Primary: Change From Baseline in Serum Phosphorus Levels at 4 Weeks — -1.73; -1.44 mg/dL — p=0.1130
Phase 3 N=336 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Chronic Kidney Disease · Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2) — -0.24; 1.27 mg / dL